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Abstract
Telomerase plays important roles in the development and progression of malignant tumors, and its activity is primarily
determined by transcriptional regulation of human telomerase reverse transcriptase (hTERT). Several mRNA alternative
splicing variants (ASVs) for hTERT have been identified, but it remains unclear whether telomerase activity is directly
associated with hTERT splicing transcripts. In this study, we developed novel real-time PCR protocols using molecular
beacons and applied to lung carcinoma cell lines and cancerous tissues for quantification of telomerase activity and three
essential hTERT deletion transcripts respectively. The results showed that lung carcinoma cell lines consistently
demonstrated telomerase activity (14.22–31.43 TPG units per 100 cells) and various hTERT alternative splicing transcripts.
For 165 lung cancer cases, telomerase activity showed significant correlation with tumor differentiation (poorly-
.moderately-.well-differentiated, P,0.01) and with histotypes (combined small cell and squamous cell carcinoma.squa-
mous cell carcinoma.adenosquamous carcinoma.adenocarcinoma, P,0.05). Although the overall hTERT transcripts were
detected in all the samples, they were not associated with telomerase activity (r=0.092, P=0.24). Telomerase activity was
significantly correlated with the transcriptional constituent ratio of a-deletion (r=-0.267, P=0.026), b-deletion (r=-0.693,
P=0.0001) and c-deletion (r=–0.614, P=0.001). The positive rate and average constituent ratio of b-deletion transcripts
(92.12%, 0.23) were higher than those of a-deletion (41.82%, 0.12) or c-deletion (16.36%, 0.18) transcripts. The combined
small-cell and squamous cell carcinomas expressed less deletion transcripts, especially b-deletion, than other histotypes,
which might explain their higher telomerase activity. In conclusion, the molecular beacon-based real-time PCR protocols are
rapid, sensitive and specific methods to quantify telomerase activity and hTERT ASVs. Telomerase activity may serve as a
reliable and effective molecular marker to assist the evaluation of histological subtype and differentiation of lung
carcinomas. Further studies on hTERT deletion splicing transcripts, rather than the overall hTERT transcripts, may improve
our understanding of telomerase regulation.
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Introduction
Normal somatic cells undergo the process of cellular senescence
because of progressive telomere shortening after each cell division.
Activation of telomerase is believed to be responsible for
maintaining sufficient telomeric length in tumor or stem cells.
These cells have overcome this proliferative block by expressing
the enzyme telomerase, which provides cells with the ability to
divide continuously. Thus, regulation of telomerase activity has
important implications for many developmental processes includ-
ing cell proliferation, differentiation and aging as well as
tumorigenesis. Telomerase activity has been detected in almost
90% of all human malignancies, making it an obvious target for
cancer diagnostic and therapeutic strategies.
The human telomerase reverse transcriptase (hTERT) is an
essential component of the holoenzyme complex that adds
telomeric repeats to the ends of chromosomes. The expression of
normal full-length hTERT correlates well with telomerase activity
and seems to be the rate-limiting factor for telomerase activity in
human cells. The hTERT gene consists of 16 exons and spans
,37 kb of genomic DNA, of which ,33 kb is intronic sequences
and the remaining ,4 kb corresponds to the hTERT mRNA
transcript. Recently, three main alternative splicing variants
(ASVs) in the reverse transcriptase motifs of hTERT were found
to be involved in the control of telomerase activity: i) a-deletion:
lacking 36 bp from exon 6 including motif A; ii) b-deletion: lacking
182 bp from exons 7 and 8, leading to a nonsense mutation and
truncating the protein before the conserved RT motifs; iii) c-
deletion: lacking 189 bp from exon 11 within motifs D and E [1].
There are several possible combinations of these alternative
splicing sites, which result in a large number of potential splicing
transcripts, but those with more than two splicing sites are unstable
and degraded too fast to be detected. Because a, b and c deletion
transcripts result in truncations or mutations in the reverse
transcriptase domain essential for catalytic activity, they are either
nonfunctional (b-deletion or c-deletion) or even have dominant-
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between hTERT gene expression and telomerase activity is
complicated.
Telomerase activity and hTERT expression were found in 67–
85% and 48–95% of lung tumors respectively [5,6], and both
were significantly associated with poor overall survival and
disease-free survival in patients with non-small cell lung cancer
(NSCLC) [6,7]. However, the relationships between telomerase
activity or hTERT and clinicopathological variables were
controversial. Lantuejoul S and coworkers reported that hTERT
expression was significantly lower in adenocarcinoma (Adc) than
in squamous cell carcinoma (Scc), basaloid carcinoma and small
cell lung cancer, and telomerase activity was lower in stage I lung
carcinomas than in other stages (II–IV) [5]. Wu TC and
coworkers demonstrated that neither telomerase activity nor
hTERT expression in NSCLCs was correlated with clinicopath-
ological characteristics such as grade, tumor stages, tumor types
or TNM values [8]. Notably, the majority of previous studies
tested only telomerase activity or overall hTERT transcripts, and
did not distinguish the different splicing variant transcripts. In the
present study, a real-time telomere repeat amplification protocol
(TRAP) with a reverse primer-linked probe (RPP), a kind of
molecular beacon probe combing the reverse primer and
fluorescence-labeled probe in one molecule, was developed for
telomerase activity quantification in lung tumor cell lines and
tissues. Another real-time PCR assay with molecular beacons was
developed to analyze the expression levels of the hTERT ASVs
in the same samples. Thus we investigated the characterization of
telomerase activity and hTERT deletion splicing transcription in
lung carcinoma, which may provide important information for
the understanding of telomerase regulation in tumorigenesis.
Methods
Tumor Material and Cell Lines
Tumor samples were obtained from 165 lung cancer patients
(115 men, 50 women; median age, 60 years; range, 31–79 years).
Within 10 minutes after surgery, tissues without necrosis and
hemorrhage were dissected from the tumor, followed by flash-
frozen in liquid nitrogen and stored at 270uC. One part of each
sample was subjected to conventional histological examination to
ensure that specimens contained at least 80% tumor cells.
Diagnosis, grading and pathologic TNM (Tumor, Node, Metas-
tasis) staging were determined independently by two experienced
pathologists according to WHO and UICC classification.
The human non-small lung cancer cell lines A549, H1299,
SPC-A1 and PAa were used as positive controls for telomerase
activity and hTERT gene expression. PAa was established from a
Chinese patient with lung adenocarcinoma and kept in our
laboratory, while other cell lines were obtained from the American
Type Culture Collection (ATCC, Manassas, VA, USA). Cells were
grown in Dulbecco’s modified Eagle’s medium (DMEM), supple-
mented with 100 mL/ L heat-inactivated fetal bovine serum
(Gibco BRL, Grand Island, NY, USA), at 37uC under 5% CO2.
Cells at 80–90% of confluency were harvested by 0.25% trypsin–
EDTA and washed with ice-cold phosphate-buffered saline (PBS,
pH 7.4). After cell counting, approximately 10
6 cells were washed
twice with PBS and pelleted by centrifugation at 2000 g for 5 min
at 4uC. The cell pellets were stored at 270uC for the telomerase
assay within six months.
Ethics Statement
This study was approved by the Peking University Institutional
Review Board with the approval No. IRB00001052-10004. All the
participants in this study have provided written consent, which has
been the review procedure of the ethics committee.
Primers and Probe Design
The traditional TRAP is a two-step assay in which telomerase
adds telomeric repeats onto the 39-end of the substrate oligonu-
cleotide, and then the extended products are amplified by
polymerase chain reaction (PCR) using TS and a reverse primer
complementary to the telomeric repeats. In this study, a real-time
TRAP assay was developed by using a reverse primer-linked probe
(RPP), which combined the reverse primer and fluorescence-
labeled probe in one molecule. The principle of this RPP-based
real-time TRAP assay is diagrammed in Fig. 1. The reverse
primer-linked probe was synthesized by Biosearch Technologies
(Novato, CA, USA). Quantification of telomerase activity was
accomplished by monitoring the fluorescent signals emitted from
the RPPs which had been incorporated into the TRAP products
(Figure S1). Molecular beacons for quantification of hTERT
overall or deletion transcripts spanned the non-splicing exons or
the deletion sites respectively, according to GenBank accession
NM_198253 (Figure S2). Primers and probes were designed using
the Primer PREMIER 5.0 and OLIGO 6.0 software respectively.
Their sequences are presented in Table S1. The delta entropy of
the second structure in each probe was calculated by Mfold
software (http://www.idtdna.com/Scitools/Applications/mFold/)
to check the stability of stem-loop. Beacon probes for hTERT and
Taqman probe for the control gene GAPDH (glyceraldehydes-3-
phosphate dehydrogenase gene) were synthesized by Sigma-
Aldrich (Saint Louis, MO, USA). All primer sets were synthesized
and purified by AuGCT Biotechnology (Beijing, China). The
specificity of PCR amplifications was assessed by 10% non-
denaturing polyacrylamide gel electrophoresis.
Real-time Quantification Assay of Telomerase Activity
The CHAPS lysis buffer was prepared as described previously
[9]. The cell pellets were resuspended in ice-cold lysis buffer
(5000 cells/ mL) and incubated for 30 min on ice. After centrifu-
gation (12 000 g, 30 min, 4uC), the supernatants were collected
carefully and rapidly frozen at 270uC. The stored tissue samples
were partially thawed and approximately 30 mg tissue was minced
under sterile conditions until a smooth consistency was obtained.
The sample was then transferred to a sterile 1.5 mL micro-
centrifuge tube, and mixed with 200 mL CHAPS lysis buffer.
RNase inhibitor (Takara Biotechnology, Dalian, China,
100 units/mL) was added to the CHAPS lysis buffer prior to the
extraction. The protein concentration was measured by the
Bradford method [10]. The final extracts were diluted to a
concentration of 2 mg/ mL protein with lysis buffer and immedi-
ately stored in aliquots at 270uC.
The total volume of reaction mixture was 20 mL and contained
16GoTaq flexi buffer, 1.8 mM MgCl2,5 0mM each of dNTP,
160 nM modified substrate oligonucleotide primer (MTS),
140 nM reverse primer-linked probe, 1unit of GoTaq DNA
polymerase (Promega Corporation, Madison, WI, USA), and 1 mL
telomerase extracts. PCR was performed using an ABI StepOne
Real-Time Cycler (Applied Biosystems, Framingham, MA, USA).
After 30 min incubation at 30uC for telomerase elongation, the
reaction mixture was heated at 95uC for 3 min to inactivate the
telomerase, followed by a 40-cycle amplification (94uC for 15 sec
and 60uC for 60 sec including 10- sec plate reading). Ten
microliters of each sample extract was incubated at 95uC for
10 min and then its one-tenth volume was added into another
parallel reaction as the heat-inactivation control. In every
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extract was used as a negative control.
TSR8 is an oligonucleotide identical to the MTS primer
extended with eight telomeric repeats AG(GGTTAG)7, which can
be used as a standard for estimating the amount of MTS primers
with telomeric repeats extended by telomerase in a given extract.
Furthermore, detection of TSR8 indicates that the amplification
step of the TRAP assay was performed effectively [11]. To
perform the TRAP assay, 1 mL of each TSR8 dilution (0.2 amol/
mL, 0.04 amol/ mL, 0.008 amol/ mL and 0.0016 amol/ mL,
respectively) was used to obtain the standard curve in which
0.001 amol TSR8 corresponds to each unit of TPG (Total
Production Generated). For a valid analysis, appropriate controls
have been included in every assay:
i) heat-inactivation control: the extract aliquot heated at 95uC
for 10 min; ii) negative control: lysis buffer substituted for protein
extract and iii) positive control: telomerase-positive cell extracts.
Sometimes, positive telomerase activity could only be detected in
the diluted extract and cannot be detected in more concentrated
extracts because the tissue extract may contain Taq polymerase
inhibitors. So for each tissue sample, at least three protein
concentrations (2 mg/ mL, 0.2 mg/ mL, 0.02 mg/ mL) were tested
in duplicates, in which the highest TPG value was considered as
the final telomerase activity.
RNA Extraction and Real-time RT-PCR Analysis of HTERT
ASVs
Total cellular RNA was extracted from frozen samples with the
TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the
manufacturer’s instructions. RNA quality was assessed by dena-
turing agarose gel electrophoresis. Only samples with sharp 18 S
and 28 S rRNA bands and without degradation were used for
further analysis. Two microgram RNA from each sample was used
for cDNA production using the M-MLV reverse transcriptase and
random hexamers (Promega Corporation, Madison, WI, USA).
The diluted cDNA (1:10 dilution) was used for the amplification of
control GAPDH to assess reverse transcription efficiency as well as
RNA integrity.
Real-time PCR was performed in a total volume of 15 mL
containing 16GoTaq flexi buffer, 5 mM MgCl2, 200 mM each of
dNTP, 1 unit of GoTaq DNA polymerase, 800 nM primers
(forward and reverse), 400 nM probes and 1 mL of diluted cDNA
(1:10 dilution). The annealing temperature was different for
different ASV. The cycling protocol consisted of 3 min initial
denaturation at 95uC and a 40-cycle amplification (94uC for
15 sec, annealing temperature for 60 sec including plate reading).
When testing each ASV transcript with the specific primer set, two
transcriptional products, with or without deletion, would be
amplified simultaneously, but the Beacon probe only hybridized
Figure 1. Linearity of the telomeric repeat amplification protocol (TRAP) using reverse primer-linked probe in cancer cell line. Cell
extracts equivalent to the indicated numbers of A549 cells were tested for telomerase activity. Results in gel electrophoresis (left), amplification plot
(above) and standard curves (below) consistently indicated the linear relationship between the telomerase activity and A549 cell number, while 5
represented a negative control.
doi:10.1371/journal.pone.0038868.g001
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[12]. The Ct value of each hTERT splicing variant was
normalized to the Ct-value of GAPDH by subtracting the
GAPDH Ct-value from the target Ct value. The relative
expression level for each target PCR was calculated using the
equation [13]: Relative expression =2
-[Ct(target)-Ct(GAPDH)]610000.
The hTERT ASV constituent ratio (calculated by dividing the
relative expression value of the overall transcripts by that of the
ASVs) was also determined for each tissue sample.
Statistical Analysis
Basic descriptive statistical data were obtained using the SPSS
11.0 software. Spearman’s correlation coefficients (r) were
calculated to assess associations among telomerase activity,
hTERT ASV expression and clinicopathological data. Differences
in telomerase activity or quantitative hTERT expression between
the analyzed subgroups were evaluated by the unpaired t-test or
one-way ANOVA. A p value ,0.05 was considered significant.
Results
Quantification of Telomerase Activity and HTERT ASVs in
Tumor Cell Lines
The sensitivity and linearity of the RPP-based real-time TRAP
assay were evaluated with non-small cell lung cancer cell line
A549. The cell pellets containing approximately 10
6 cells were
resuspended in 200 mL CHAPS lysis buffer, so the extracts
corresponded to telomerase activity of 5000 cells per microliter.
The telomerase extracts were serial diluted from 1000 to 1 cell per
microliter, and 1 mL extract was used in the quantification of
telomerase activity in triplicates. The telomerase in extracts would
add telomeric repeats onto the 3’-end of the substrate oligonucle-
otide (MTS) in the first incubation step and the products were
amplified as template in the subsequent PCR process. As shown in
Figure 1, using the TRAP-polyacrylamide gel electrophoresis
(TRAP-PAGE) assay, telomerase activity could be detected in at
least ten A549 cells, indicated by the presence of a visible
hexanucleotide ladder of PCR products on the polyacrylamide gel.
However, using RPP-based real-time TRAP assay, telomerase
activity could be detected in as few as one A549 cell. A linear
relationship was also observed between telomerase activity and the
logarithm of the number of cells ranging from 1 to 1000 cells. The
correlation coefficient calculated from the linear regression model
was up to 96.4%. Including telomerase extraction, the RPP-based
real-time TRAP assay could be finished within three hours,
whereas the TRAP-PAGE would take at least 5 hours. Impor-
tantly, the RPP-based real-time TRAP assay was accurately
quantitative and reproducible. As shown in Table 1, cell lines
A549, H1299, SPC-A1 and PAa consistently demonstrated
telomerase activity from 14.22 to 31.43 TPG units per 100 cells.
Molecular beacons are sensitive and specific because the probes
are not hydrolyzed in the amplification and only recognize the
perfectly complementary targets. In the quantification of hTERT
ASVs, the molecular beacon probe anneals to the corresponding
transcripts and monitors the synthesis of the specific nucleic acids
in real time. For example, the probe H1810 is complementary to
the DNA sequence in the junction of exon 3 and exon 4 of
hTERT gene, and would hybridize to all the hTERT transcripts
and therefore detect overall hTERT transcripts, including normal
and variant splicing transcripts. However, the probe A2173,
B2331 and R2699 only detect the a, b or c deletion transcripts
respectively. By using the newly developed quantification protocol,
in SPC-A1 cells, all of the three deletion splicing transcripts were
detected, with the ratio 0.21, 0.26 and 0.04 for a, b or c deletion
transcripts respectively (Table 1 and Figure 2), which would
induce partial nonfunctional transcripts and may explain its low
telomerase activity. In other cell lines, the c-deletion transcript was
not detected and the expression levels of a-deletion transcripts
(range, 0.25–0.44) were higher than b deletion transcripts
(Table 1).
Quantification of Telomerase Activity and HTERT ASVs in
Lung Tumor Samples
In the TRAP assay of tumor tissue sample, the results in both
polyacrylamide gel electrophoresis and amplification curves of
RPP-based real-time TRAP indicated the linear relationship
between the telomerase activity and logarithm of protein
concentration (Figure 3). In one case of squamous cell carcinoma,
telomerase activity could be detected at a protein concentration as
low as nearly 0.002 mg/ mL. To get reliable quantitative TRAP
result, at least three protein concentrations (0.02, 0.2 and 2 mg/
mL) in duplicate for each tumor sample were analyzed with two
separate experiments.
In all 165 specimens of lung tumor tissues, telomerase activity
ranged from 0.39–482.46 TPG units (Table 2). The average
telomerase activity in male patients was significantly higher than
Table 1. Quantification of telomerase activity and hTERT alternative splicing variants in tumor cell lines.
Cell lines Source
Telomerase
activity*
(TPG units)
hTERT
overall
transcripts
# hTERT alternative splicing variants
Relative expression
# Constituent ratio
w
a-deletion
transcripts
b-deletion
transcripts
c-deletion
transcripts
a-deletion
transcripts
b-deletion
transcripts
c-deletion
transcripts
A549 Lung adenocarcinoma 31.4366.47 17.0062.92 4.2562.14 2.4460.68 Not found 0.25 0.14 Not found
SPC-A1 Lung adenocarcinoma 14.2269.27 15.1462.70 3.2260.81 3.9760.81 0.6160.04 0.21 0.26 0.04
H1299 Lung large cell carcinoma 20.3762.76 5.6160.88 2.4461.62 0.4660.02 Not found 0.44 0.08 Not found
PAa Lung adenocarcinoma 21.4263.57 14.8063.73 4.2561.17 1.9861.61 Not found 0.29 0.13 Not found
hTERT: human telomerase reverse transcriptase.
*The means6standard deviation of duplicate determinations.
#The means6standard deviation of triplicate determinations.
wIt was calculated by dividing the relative expression value of the overall transcripts by that of each deletion.
doi:10.1371/journal.pone.0038868.t001
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negatively associated with tumor differentiation (r=0.022,
P=0.005), in which the poorly differentiated tumors showed the
highest telomerase activity. Telomerase activity was significantly
different among the four main histological phenotypes of lung
carcinomas (P=0.001), which was also evaluated in pairs. The
combined small cell and squamous cell carcinoma (CSS) showed
the highest telomerase activity (vs. other three histotypes,
P=0.001), followed by Scc and adenosquamous carcinoma
(ASc) (vs. other three histotypes, P=0.025 respectively), while
Adc showed the lowest telomerase activity (vs. other three
histotypes, P=0.001). No association between the telomerase
activity and TNM stage was found in this study (P.0.05).
Quantification of the overall and deletion splicing hTERT
transcripts were performed in all of tumor samples. In Spearman’s
analysis, there was no significant correlation between the
expression of hTERT overall transcripts and telomerase activity
(r=0.092, P=0.241), and between the expression of hTERT
overall transcripts and any clinicopathologic parameter (P.0.05).
The a, b and c deletion transcripts were detected in 41.82%,
92.12% and 16.36% of patients, and their average constituent
ratio was 0.12, 0.23 and 0.18 respectively. Only 16 patients
expressed all of the three deletion transcripts at the same time. It
was remarkable that all of three deletion transcripts’ constituent
ratios were significantly correlated with the telomerase activity,
while the correlation coefficient was –0.267 for a-deletion
transcript (P=0.026), –0.693 for b-deletion transcript
(P=0.0001) and –0.614 for c-deletion transcript (P=0.001),
respectively. In male patients, the average constituent ratios of
the three deletions were lower than those in female patients,
consistent with the higher telomerase activity among them.
However, only b-deletion and c-deletion showed significant
difference between male and female patients (P=0.006,
P=0.027, respectively). As for pairwise comparisons between
histologic subtypes and three deletion transcriptional constituent
ratios, the CSS showed significant lower constituent ratio in b-
deletion (P=0.011) and c-deletion (P=0.015) than Adc. The Scc
only presented lower constituent ratio in c-deletion (P=0.006)
than Adc. There was no significant association between any
deletion transcriptional constituent ratio and tumor differentiation,
stage or lymph node metastasis. Furthermore, the patients with
pleural metastasis showed significant higher transcriptional con-
stituent ratio in b-deletion (P=0.041), but not in other two
deletions (P=0.227 and P=0.735 respectively).
Discussion
Since telomerase is expressed in almost 90% of all human
cancers, there has been great interest in developing a telomerase
assay suitable for clinical testing [14]. As an end-point and semi-
quantitative analysis, the traditional TRAP is low-throughput,
limited in accurate quantification and likely to be false negative
because the PCR amplification efficiency may be inhibited by the
protein in cell extract. Quantification of telomerase activity using
real-time analysis is more precise because it relies on Ct values
determined during the exponential phase of PCR at relatively low
concentrations of PCR product before saturation or plateau.
Previous real-time quantitative TRAP with fluorescent dyes or
Taqman probe is less specific and more limited in its quantitative
potential because of no one-to-one correspondence between
fluorescence and PCR product [15,16]. Here, we described a
novel quantitative TRAP assay by using a reverse primer-linked
probe (RPP). RPP is a molecular switch to detect DNA
amplification by utilizing energy transfer between fluorophore
(FAM) and quencher (DABSYL). The OFF to ON transition
occurs when the conformation of the RPP changes from a
Figure 2. Quantification of hTERT deletion splicing transcripts in SPC-A1 cell line using molecular beacons. Representative linear
amplification curves were shown for quantitative detection of overall hTERT (A), a-deletion (B), b-deletion (C) and c-deletion (D) transcripts
respectively. GAPDH served as an internal control. NC: negative control.
doi:10.1371/journal.pone.0038868.g002
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extended structure. This structural change is achieved when one
RPP is incorporated into a double-stranded DNA molecule by
PCR. The amplification can be monitored by directly measuring
the fluorescence of the reaction mixture. In this study, telomerase
activity demonstrated satisfactory linear relationships with the
logarithm of cultured cell number or protein concentration in
proper range. Telomerase activity could be detected in as few as
one cultured tumor cell or as low as 0.002 mg protein from tumor
tissue. Consistent with previous report, the fluorescein-probe-
based real-time TRAP assay gave more rapid, accurate results for
telomerase activity quantification than traditional TRAP with gel
electrophoresis [17]. In our previous study, we examined the
telomerase activity of 60 lung cancer tissues using SYBR Green
real-time TRAP, a relative quantitative analysis, and only found
the difference in telomerase activity between NSCLC and CSS
[9]. In this study, we applied the RPP-based real-time TRAP to a
larger number of lung tumor tissue samples (165 cases) and used
standard curve analysis. A significant difference in telomerase
activity among four histological types was found: CSS. Scc .
ASc . Adc, which was consistent with Fujiwara’s report [18].
Ohmura and Maniwa have reported higher telomerase activity in
NSCLC (42.3 and 75.24 TPG units respectively), in which they
examined 60 and 40 cases respectively, and used semi-quantitative
methods [19,20]. We consider that such contradictions could be
attributed to diversity in populations and sample size, and
especially to the different techniques used to detect telomerase
activity. It was also conflicting in literatures whether the level of
telomerase activity was correlated with the aggressive clinicopath-
ological features, such as tumor differentiation and TNM stage
[6,19–21]. Using the RPP-based real-time TRAP, we observed a
strong correlation between telomerase activity and tumor differ-
entiation. It was interesting that difference in telomerase activity
between male and female patients was observed in this study. That
female patients mainly suffered from Adc, which had lower
telomerase activity than other subtypes, may contribute to their
lower telomerase activity than male patients. Thus, telomerase
activity appears to be a useful marker in determining histological
type and differentiation in lung carcinomas.
Some authors claimed that the detection of hTERT mRNA by
RT-PCR or in situ hybridization could be used to evaluate the
telomerase activity [5]. However, the transcriptional and post-
transcriptional regulation of hTERT was complex and not fully
elucidated. Previously, primer set or Taqman probe spanning the
deletion site was used in most studies for splicing variant
examinations [22–26]. However, these primer sets or probes
might amplify both the full-length transcripts and deletion
transcripts because of the staggered annealing with mixed
templates. In the present study, we developed a quantitative assay
using molecular beacons and detected all of three deletion
transcripts in SPC-A1 cells. We found a relative high constituent
ratio (range, 0.21–0.44) for the a-deletion transcripts in the four
Figure 3. Linearity of the telomeric repeat amplification protocol (TRAP) using reverse primer-linked probe in tumor tissue. Serial
diluted protein extracts from 2 mg to 0.0002 mg were tested for telomerase activity in one case of squamous cell carcinoma. Results in gel
electrophoresis (left), amplification plot (above) and standard curves (below) consistently indicated the linear relationship between the telomerase
activity and protein concentration, while 6 represented a negative control.
doi:10.1371/journal.pone.0038868.g003
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lower constituent ratio (range, 0.06–0.15) previously [1,25,27].
This may be attributed to our use of more specific molecular
beacon, rather than the semi-quantitative nested PCR assays. The
patterns of hTERT ASVs were shown to be varied in breast, liver,
gastric, colon, thyroid and lung tumors, in which the positive rates
of hTERT ASVs were probably overestimated by amplifying a
region spanning both deletion sites [1,11,21–24,26,28]. Our
quantitative assay for each deletion transcript provides a solution
to accurately quantify the ASV expression and evaluate its
relationship with clinic-pathological parameters.
In this study, no association between the overall hTERT
transcripts expression and telomerase activity was observed,
consistent with previous reports in other tumors [29,30], which
indicated that it was not reasonable to substitute the overall
hTERT mRNA detection for telomerase activity evaluation. We
found that more than 92% of patients expressed at least one
deletion transcription, but only 9.7% expressed all of the three
deletion transcripts. Notably, the constituent ratios of the three
deletion transcripts were significantly correlated with telomerase
activity. The b-deletion transcripts were the most common splicing
variants in most lung carcinomas and showed the strongest
correlation with telomerase activity. This is similar to the previous
findings in other tumor types [11,22–24,26]. Our results showed
that the constituent ratios of deletion transcripts, especially the b-
deletion, were less in CSS than in NSCLC, which might explain
CSS’ higher telomerase activity. The three deletion ASVs didn’t
show any correlation with tumor differentiation, stage or lymph
node metastasis. Interestingly, we found that pleural metastasis
group presented significant higher b-deletion transcript, which
could be due to the high percentage of Adc patients in this group.
The fact that there is a significant heterogeneity in the expression
of hTERT ASVs raises many questions about the possible role of
the alternate transcripts of hTERT in the regulation of telomerase
and in malignant transformation. Alternative splicing is not
random and often inhibits the expression of hTERT protein
containing functional reverse transcriptase domains. Telomerase
regulation by its splicing variants might be cell type-specific or
histotype-specific, as suggested by the precise patterns of splicing
that occur in particular cell types during development [3]. In two
cases of adenocarcinomas, we did not find any deletion transcript,
whereas, we found lower telomerase activity (,1.5 TPG unit) and
higher expression of overall hTERT transcripts (.15). A possible
explanation for this discordance could be the existence of other
Table 2. Quantification of telomerase activity and hTERT alternative splicing variants in lung tumor tissues.
Telomerase activity*
(TPG units)
hTERT overall
transcripts
# hTERT alternative splicing variants
Variable n a-deletion transcripts b-deletion transcripts c-deletion transcripts
n
Constituent
ratio
w n
Constituent
ratio
w n
Constituent
ratio
w
Sex
Male 115 30.72619.44 41.92622.91 50 0.1160.04 107 0.2060.11 19 0.0960.04
Female 50 12.2669.27 25.24610.12 19 0.1360.07 45 0.3160.14 8 0.3960.11
Histological subtype
Adc 43 7.3264.37 29.24613.24 12 0.1760.09 39 0.2860.16 6 0.4160.13
Scc 73 29.11612.95 51.77617.31 33 0.1160.05 66 0.1960.10 14 0.1060.04
ASc 27 21.82612.21 19.4569.39 11 0.0960.02 26 0.2460.09 2 0.2460.10
CSS 12 79.80633.11 36.14615.47 10 0.0860.02 12 0.0860.02 4 0.0660.04
Other 10 15.9467.86 8.7463.75 3 0.2460.12 9 0.5060.30 1 0.3360.16
Differentiation
Well 30 8.0964.77 36.70614.46 6 0.1760.06 25 0.2260.15 4 0.2060.13
Moderately 105 24.14610.03 41.34619.36 43 0.1160.08 98 0.2460.11 16 0.2060.08
Poorly 30 46.35616.72 20.6867.98 20 0.1260.05 30 0.2260.11 7 0.1860.09
Stage
I/II 98 26.56611.48 20.9367.33 46 0.1360.10 92 0.2460.15 16 0.1960.09
III/IV 67 23.03611.09 60.17627.49 23 0.0960.06 61 0.2260.16 11 0.1660.07
Pleural metastasis
Yes 83 18.4269.72 31.37616.39 31 0.1460.05 77 0.2760.18 10 0.2060.12
No 82 31.91613.69 42.42618.35 38 0.1060.04 75 0.1960.10 17 0.1760.05
Lymph node metastasis
Yes 91 21.5669.77 46.45618.47 35 0.1060.04 82 0.2660.11 13 0.1860.11
No 74 29.52614.72 25.07610.48 34 0.1360.09 70 0.2060.13 14 0.1760.12
hTERT: human telomerase reverse transcriptase; Adc, adenocarcinoma; Scc, squamous cell carcinoma; ASc, adenosquamous carcinoma; CSS, combined small cell and
squamous cell carcinoma.
*The means6standard deviation of duplicate determinations.
#The means6standard deviation of triplicate determinations.
wIt was calculated by dividing the relative expression value of the overall transcripts by that of each deletion.
doi:10.1371/journal.pone.0038868.t002
Telomerase Transcription in Lung Carcinoma
PLoS ONE | www.plosone.org 7 June 2012 | Volume 7 | Issue 6 | e38868mechanism of transcriptional regulation, such as insertions. The
complication in the regulation of hTERT transcription in lung
carcinoma raised some questions in selecting suitable markers to
evaluate telomerase activity. The real-time TRAP assay may be a
quantitative, reproducible and time-efficient testing tool to directly
evaluate telomerase activity of clinical tumor tissues. When the
fresh or frozen tissue is not available to test telomerase activity, the
detection of the hTERT transcripts including the overall and
deletion ASVs, may be a suitable marker for telomerase activity.
In conclusion, we have developed highly specific, sensitive and
rapid quantitative PCR protocols for determination of telomerase
activity and hTERT deletion transcripts. Quantification of the
telomerase activity may serve as a reliable and effective tool to
assist the evaluation of histological subtype and differentiation of
lung carcinomas. Further research on hTERT ASVs, rather than
the overall hTERT transcript, may improve our understanding of
telomerase activity regulation.
Supporting Information
Figure S1 Principle of the quantitative TRAP with the
reverse primer-linked probe (RPP), which combines the
reverse primer and fluorescence-labeled probe in one
molecule and is a kind of molecular beacon. At the initial
incubation step, telomeric repeats are added to the 39 end of the
substrate primer (MTS) by active telomerase. In the preceding
PCR cycles, the RPP anneals to the 39 end of telomerase extension
product in the reverse direction. The annealing temperature and
time allows the fast priming reaction to be finished sufficiently and
accurately in the exact complementary site. After this step, both
ends of the products are not the telomeric repeats, but
complementary to the MTS and RPP. RPP is a molecular switch
to detect DNA amplification by utilizing energy transfer between
fluorophore (FAM) and quencher (Dabsyl). The OFF to ON
transition occurs when the conformation of the RPP changes from
a ‘‘closed’’ intra-molecular stem-loop structure to an ‘‘open’’
extended structure. This structural change is achieved when one
RPP is incorporated into a double-stranded DNA molecule by
PCR. The amplification can be monitored by directly measuring
the fluorescence of the reaction mixture. In this assay, the
fluorescent signal is only observed after PCR amplification of
telomerase-specific products, thereby eliminating non-specific
background.
(TIF)
Figure S2 Principle of the detection of hTERT deletion
splicing transcripts by molecular beacons. (Top) Locations
of telomerase-specific T motif, seven conserved reverse transcrip-
tase motifs (1, 2, A, B’, C, D and E), exons 3–13 and deletion sites
are indicated. (Bottom) In the absence of hTERT deletion splicing
transcriptional product, the probe does not emit fluorescence, as
the quencher is close to the fluorophore in the stem-loop structure.
Hybridization of the probe sequences with the splicing product
separates the quencher from the fluorphore and restores
fluorescence.
(TIF)
Table S1 Primers and probes used in real-time quan-
tification of telomerase activity and hTERT transcrip-
tion.
(DOC)
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